Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 10/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29158125 | 0.81 | AGBL2 (0.44) | ALDH1A1DPP4TSHR | |
| SCHEMBL15545611 | 0.81 | AGBL2 (0.42) | ADORA2AALDH1A1ADORA1TSHRMEN1 | |
| SCHEMBL22557745 | 0.80 | DPP4 (0.44) | ALDH1A1DPP4 | |
| SCHEMBL16680964 | 0.79 | ATM (0.45) | ALDH1A1MEN1KMT2A | |
| SCHEMBL16680963 | 0.79 | ATM (0.45) | ALDH1A1MEN1KMT2A | |
| SCHEMBL22557290 | 0.79 | DPP4 (0.47) | ALDH1A1DPP4MAPK1TSHR | |
| SCHEMBL15545023 | 0.76 | SLC13A5 (0.40) | ALDH1A1MAPK1TSHRNPSR1MEN1 | |
| SCHEMBL22556967 | 0.74 | DPP4 (0.41) | ALDH1A1DPP4MAPK1TSHR | |
| SCHEMBL30753587 | 0.74 | DPP4 (0.41) | ALDH1A1DPP4MAPK1TSHR | |
| SCHEMBL15544876 | 0.73 | ATM (0.41) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-2870144-B1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9555044-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| EP-2870144-A1 | OREXIN RECEPTOR ANTAGONISTS | Heptares Therapeutics Limited (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| WO-2014006402-A1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ADORA2A 291/4885ALDH1A1 3165/4885DPP4 1640/4885 |
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | ADORA2A 291/4885ALDH1A1 3165/4885DPP4 1640/4885 |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ADORA2A 291/4885ALDH1A1 3165/4885DPP4 1640/4885 |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ADORA2A 291/4885ALDH1A1 3165/4885DPP4 1640/4885 |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ADORA2A 291/4885ALDH1A1 3165/4885DPP4 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.